Emerald
Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (Emerald) has
completed the purchase of the remaining shares of Northern Vine Canada
Inc. (Northern Vine) from Abattis Bioceuticals Corp. (Abattis) (CSE:
ATT; OTC: ATTBF) for $2 million in cash and 1,093,938 common shares of
Emerald (with a deemed value of $4 million, based on the trailing 30 day
VWAP of Emerald shares as of July 19, 2018). This transaction,
announced on July 19th, increases Emerald’s ownership of
Northern Vine from 65% to 100%. Northern Vine is a Licensed Dealer (LD)
under the provisions of the Canadian Controlled Drugs and Substances
Act.
The dealer license allows Emerald to
participate in the growing market for cannabis analytical testing, which
Emerald expects to grow in conjunction with increasing cannabis
production volumes in Canada. Northern Vine will operate independently
of Emerald and is committed to serving all clients, including Licensed
Producers and patient-growers. Legalization of cannabis for medical
purposes and the upcoming legalization of cannabis for recreational
purposes is expected to drive demand for analytical testing services to
assess potency and concentration of toxic materials.
This
acquisition also allows Emerald to leverage Northern Vine’s dealer
license to advance research plans to develop cannabis formulations
supporting new products for both recreational purposes and to treat a
broad spectrum of human conditions and diseases.
The
Agreement includes a milestone payment in the form of common shares of
Emerald valued at $4 million if Northern Vine and/or Emerald receive
gross revenue of $10 million from the sale of products or services
introduced by Abattis.
About Emerald Health Therapeutics, Inc.
Emerald
Health Therapeutics (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a
Licensed Producer under Canada’s Access to Cannabis for Medical Purposes
Regulations and produces and sells dried cannabis and cannabis oil for
medical purposes. Emerald is preparing to serve the fully legalized
Canadian adult-use cannabis market starting October 17, 2018. Emerald
owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1
million square foot greenhouse in Delta, BC and is now in commercial
production. It owns Agro-Biotech, a Québec-based licensed cannabis
grower with a 75,000 square foot indoor facility and is planning to add a
500,000 square foot greenhouse in Metro Vancouver. Emerald’s team is
highly experienced in life sciences, product development, large-scale
agri-business, and marketing, and is focused on developing value-added
cannabis-based products with potential wellness and medical benefits.
Emerald is part of the Emerald Health group,
which is broadly focused on developing pharmaceutical, botanical, and
nutraceutical products that may provide wellness and medical benefits by
interacting with the human body’s endocannabinoid system.
No comments:
Post a Comment